Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Inspire Pharmaceuticals |
---|---|
Information provided by: | Inspire Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00210067 |
The purpose of this trial is to access the tolerability of INS37217 Intravitreal Injection when administered intravitreally in subjects with macula-on or macula-off rhegmatogenous retinal detachment (RRD).
Condition | Intervention | Phase |
---|---|---|
Retinal Detachment |
Drug: denufosol tetrasodium (INS37217) Intravitreal Injection |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Official Title: | A Double-Masked, Randomized, Dose-Ranging Study of a Single Intravitreal (IVT) Injection of INS37217 Intravitreal Injection in Subjects With Retinal Detachment |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 06-101 |
Study First Received: | September 13, 2005 |
Last Updated: | November 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00210067 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Retinal Detachment Eye Diseases Retinal Diseases |
Retinal Detachment Eye Diseases Retinal Diseases |